Long-acting antiretroviral therapy

dc.creatorSoriano, Vicente (1)
dc.creatorBarreiro, Pablo
dc.creatorMendoza, Carmen de
dc.date.accessioned2020-10-06T15:03:17Z
dc.date.accessioned2023-03-07T19:28:46Z
dc.date.available2020-10-06T15:03:17Z
dc.date.available2023-03-07T19:28:46Z
dc.date.created2020-10-06T15:03:17Z
dc.identifier14761122
dc.identifierhttps://reunir.unir.net/handle/123456789/10640
dc.identifierhttps://doi.org/10.1038/s41563-020-0731-7
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5904976
dc.description.abstractNanoformulations of cabotegravir prodrugs have been developed to prolong the pharmacokinetics of the antiretroviral agent. They can be present in the plasma of mice and non-human primates for a year following a single injection.
dc.languageeng
dc.publisherNature Materials
dc.relation;vol. 19, nº 8
dc.relationhttps://www.nature.com/articles/s41563-020-0731-7
dc.rightsopenAccess
dc.subjectScopus
dc.subjectJCR
dc.titleLong-acting antiretroviral therapy
dc.typeArticulo Revista Indexada


Este ítem pertenece a la siguiente institución